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ABSTRACT: 
 
 
Background:  Since the time of NACO Antiretroviral (ART) role-out, generic ART has 
been the mainstay of therapy. There are many studies documenting the efficacy of 
generic ART but with the passage of time, treatment failure is on the rise. There are not 
many centres which provide free second line antiretroviral therapy. Through this study 
we aim to determine factors which contribute towards treatment failure in our cohort of 
patients.  
 
 
Methodology: This was a matched case-control study assessing predictors for treatment 
failure in our cohort who had been on Anti-retroviral therapy for at least a year. We 
identified 42 patients (Cases) with documented treatment failure and 42 sex, age and 
duration of therapy-matched controls. Using a structured proforma, we collected 
information from the out-patient and in-patient charts of the ID clinic Cohort in CMC, 
Vellore. A set of predetermined variables were studied as potential risk factors for 
treatment failure on ART.  
 
 
 
  
 
Results: Univariate analysis showed significant association with 1)Self-reported 
adherence<95%[OR 12.81(95%CI 1.54-281.45)], 2)Treatment interruptions in adherent 
cases[OR 9.56(95%CI 1.11-213.35)], 3)Past inappropriate therapies [OR 9.65(95%CI 
1.12-215.94)], 4)Diarrhoea [OR 16.40(95%CI 2.02-355.96)], 5)GI opportunistic 
Infections [OR 11.06(95%CI 1.31-244.27)] and 6)Drug Toxicity [OR 3.69(95%CI 1.15-
12.35)]. 
 In multiple logistic regression analysis, we found independent risk factors of treatment 
failure to be: Self-reported non-adherence (<95%) with OR 15.46(95%CI 1.55 – 154.08), 
drug toxicity – OR 4.13(95%CI 1.095 – 15.534) and history of diarrhoea – OR 
23.446(95%CI 2.572 – 213.70). 
 
 
 
Conclusion: This study reveals that besides adherence to therapy, presence of diarrhoea 
and occurrence of drug toxicity are significant risk factors associated with failure of anti-
retroviral therapy. There is a need for further prospective studies to elucidate their role in 
development of treatment failure on ART and thus help development of targeted 
interventions. 
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Background:  Since the time of NACO Antiretroviral (ART) role-out, generic ART has been the 
mainstay of therapy. There are many studies documenting the efficacy of generic ART but with the 
passage of time, treatment failure is on the rise. There are not many centres which provide free second 
line antiretroviral therapy. Through this study we aim to determine factors which contribute towards 
treatment failure in our cohort of patients.  
Methodology: This was a matched case-control study assessing predictors for treatment failure in our 
cohort who had been on Anti-retroviral therapy for at least a year. We identified 42 patients (Cases) with 
documented treatment failure and 42 sex, age and duration of therapy-matched controls. Using a 
structured proforma, we collected information from the out-patient and in-patient charts of the ID clinic 
Cohort in CMC, Vellore. A set of predetermined variables were studied as potential risk factors for 
treatment failure on ART.  
Results: Univariate analysis showed significant association with 1)Self-reported adherence<95%[OR 
12.81(95%CI 1.54-281.45)], 2)Treatment interruptions in adherent cases[OR 9.56(95%CI 1.11-213.35)], 
3)Past inappropriate therapies [OR 9.65(95%CI 1.12-215.94)], 4)Diarrhoea [OR 16.40(95%CI 2.02-
355.96)], 5)GI opportunistic Infections [OR 11.06(95%CI 1.31-244.27)] and 6)Drug Toxicity [OR 
3.69(95%CI 1.15-12.35)]. 
 In multiple logistic regression analysis, we found independent risk factors of treatment failure to be: Self-
reported non-adherence (<95%) with OR 15.46(95%CI 1.55 – 154.08), drug toxicity – OR 4.13(95%CI 
1.095 – 15.534) and history of diarrhoea – OR 23.446(95%CI 2.572 – 213.70). 
Conclusion: This study reveals that besides adherence to therapy, presence of diarrhoea and occurrence 
of drug toxicity are significant risk factors associated with failure of anti-retroviral therapy. There is a 
need for further prospective studies to elucidate their role in development of treatment failure on ART and 
thus help development of targeted interventions. 
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INTRODUCTION 
 
Epidemiology of HIV/AIDS: 
 
The growing epidemic of HIV infection continues to be a challenge to mankind. 
The prevalence of the HIV infection as predicted by the WHO 10 years back was only 
half the number as the current prevalence of the PLWHA. The number of people living 
with HIV worldwide continues to grow, estimated to have reached 33.4 million (31.1 
million–35.8 million) by 2008. The number of people living with HIV infection in 2008 
was more than 20% higher than the number in 2000, and the prevalence was roughly 
threefold higher than in 1990. 
 
The prevalence is not uniform. There is a considerable geographical variation 
with the majority of the infection in the developing countries like Africa and India. The 
prevalence of HIV in India is 2 million to 3.1 million [1]. There is growing population of 
HIV affected people in India and along with other communicable diseases it poses a great 
threat to humanity [2]. 
 
Trends in HIV prevalence: 
 
The growing population of people with HIV infection reflects the combined 
effects of continued high rates of new HIV infections and the beneficial impact of 
antiretroviral therapy.  As of December 2008, approximately 4 million people in low- 
and middle-income countries were receiving antiretroviral therapy—a 10-fold increase 
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over five years (World Health Organization, United Nations Children’s Fund, UNAIDS, 
2009). The latest epidemiological data indicate that globally the spread of HIV appears to 
have peaked in 1996, when 3.5 million [3.2 million–3.8 million] new HIV infections 
occurred. In 2008, the estimated number of new HIV infections was approximately 30% 
lower than the peak of the epidemic which occurred 12 years ago. 
 
HIV-related mortality appears to have peaked in 2004, when 2.2 million [1.9 
million–2.6 million] deaths occurred. The estimated number of AIDS related deaths in 
2008 was roughly 10% lower than in 2004. 
                 
Impact of Anti-retroviral therapy: 
 
With the increase in the number of people living with HIV infection, there has 
been an increase in the understanding of the disease process and also the availability of 
the drugs in the treatment [3]. Previous decade has seen an evolution in the treatment of 
HIV infection from Monotherapy to Combination therapy in India [4]. The combination 
therapy has greatly reduced the viral load, improved the quality of life and decreases the 
resistance. In India, there are 226 ART centres which distribute free combination therapy. 
There are around 280,954 patients in India alive and taking free ART through the NACO 
ART centres [5]. Though the resources are limited, India has devised effective ways of 
distributing ART drugs [6].   
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Problem statement – Anti-retroviral therapy failure : 
 
The challenge that faces the ID physicians/physicians involved with the treatment 
of PLWHA with HAART is that of failure of virological and immunological response 
over the course of therapy. Different studies have quoted different rates of incidence of 
treatment failure and it differs with various factors. There is a need to address the 
problem of treatment failure and to look into the factors that predispose to the same. 
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AIMS : 
 
To study the profile of patients with treatment failure (virological or immunological or 
clinical) on generic Anti-retroviral therapy in the cohort of patients followed up at the ID 
clinic, CMC Vellore. 
 
 
 
OBJECTIVES :  
 
1. To study the profile of individuals on generic ART. 
2. To determine putative risk factors possibly contributing towards development of 
treatment failure in a cohort of individuals on generic ART.   
3. To study the patterns of genotypic resistant mutations and correlating with 
clinical outcomes in patients with treatment failure on ART. 
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 LITERATURE REVIEW  
 
Stages and Natural history of HIV infection: 
HIV-1 infection is divided into stages of primary infection with seroconversion, 
clinical latency, early symptomatic disease and AIDS. The mode of acquisition is mainly 
through heterosexual transmission in developing countries; and in countries such as the 
United States, men who have sex with men (MSM) also account for a sizeable number of 
HIV/AIDS diagnoses. Risk factors for transmission include high plasma HIV viral load 
and presence of ulcerative genital sexually transmitted diseases.  
Symptomatic primary HIV infection occurs in many patients and has been 
reported in all major risk categories. The presence of symptoms and a prolonged illness 
correlates with more rapid progression to AIDS. 
            The period of early HIV disease extends from seroconversion to six months 
following HIV transmission. During the period of asymptomatic infection, patients 
generally have no findings on physical examination except for lymphadenopathy. 
Despite the lack of symptoms, high rates of HIV replication and CD4 T cell destruction 
may be occurring.  
             The stage of early symptomatic HIV infection is called "Class B" according to 
the CDC 1993 classification system and was formerly called "AIDS-related complex". 
The most substantive change in the classification system was the inclusion of all patients 
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with a CD4 cell count below 200/mm3 as having AIDS, regardless of the presence or 
absence of symptoms. 
 
 
Graphical representation of Typical course of an untreated HIV-infected individual 
Adapted from www.uptodate.com 
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Pathophysiology of HIV  infection: 
 
HIV belongs to the lentivirus group of the retrovirus family. There are at least 
two types, HIV-1 and HIV-2. HIV-2 is almost entirely confined to West Africa although 
there is evidence of some spread to the Indian subcontinent. Retroviruses are 
characterized by the possession of the enzyme reverse transcriptase, which allows viral 
RNA to be transcribed into DNA, and thence incorporated into the host cell genome. 
Reverse transcription is an error-prone process with a significant rate of misincorporation 
of bases. This, combined with a high rate of viral turnover, leads to considerable genetic 
variation and a diversity of viral subtypes or clades.  
On the basis of DNA sequencing, HIV-1 is divided into two subtypes:  
 Group M (major) subtypes. There are at least 10, which are denoted A-J. There is 
a predominance of subtype B in Europe, North America and Australia, but areas 
of central and sub-Saharan Africa have multiple M subtypes.  
 Group O (outlier) subtypes. These are highly divergent from group M and are 
confined to small numbers centred on the Cameroons. 
Recombination of viral material generates an array of circulating recombinant forms 
(CRFs), which increases the genetic diversity that may be encountered. 
The interrelationship between HIV and the host immune system is the basis of the 
pathogenesis of HIV disease. The host cellular receptor that is recognized by HIV surface 
glycoprotein is the CD4 molecule, which defines the cell populations that are susceptible 
to infection. The interaction between CD4 and HIV surface glycoprotein together with 
chemokine co-receptors CCR5 and CXCR4 is responsible for HIV entry into cells. 
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Mutations in the gene expressing the receptor for chemokine CCR5 may impair entry of 
HIV into cells and therefore confer some resistance to this infection. Auxiliary viral 
proteins such as those coded by the Nef gene have a role in influencing host cell membrane 
proteins and signal transduction pathways. CD4 receptors and HIV surface glycoprotein 
interactions mediate the process of syncytium formation, which is a cytopathic effect of 
HIV infection.  
 
             Studies of viral turnover in HIV-infected individuals have demonstrated a virus 
half-life in the circulation of about 6 hours. To maintain observed levels of plasma 
viraemia, 10
8
-10
9
 virus particles need to be released and cleared daily. Virus production by 
infected cells lasts for about 2 days and is probably limited by the death of the cell, owing 
to direct HIV effects, linking HIV replication to the process of CD4 destruction and 
depletion. Studies suggest that immunopathogenesis is a result of defective T cell 
homeostasis in HIV infection. The progressive and severe depletion of CD4 helper 
lymphocytes has profound repercussions for the functioning of the immune system. Cell-
mediated immunodeficiency, which is the major consequence, leaves the host open to 
infections with intracellular pathogens, whilst the coexisting antibody abnormalities 
predispose to infections with capsulated bacteria. HIV also has a direct effect on certain 
tissues, notably the nervous system.  
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The replication cycle of HIV (depicted above) 
Of note, is also the site of action of various anti-retroviral agents, viz.Fusion inhibitors, 
Reverse transcriptase inhibitors, Protease inhibitors, Integrase inhibitors etc,. 
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Anti-retroviral therapy: 
 
The currently available ARV drugs cannot eradicate the HIV infection from the 
human body. This is because a pool of latently infected CD4 cells is established during 
the earliest stages of acute HIV infection and persists within the organs/cells and fluids 
(e.g., liver and lymphoid tissue) even with prolonged suppression of plasma viraemia to 
<50 copies/ml by antiretroviral therapy. The goal of therapy is essentially to reconstitute 
immune status both quantitatively and qualitatively and there by improve quality of life 
by preventing opportunistic infections as well as HIV-associated illnesses. 
According to the NACO programme guidelines for treatment of HIV, all persons 
registered for care and treatment at ART centres should have their full history taken and 
undergo clinical examination, including determining the clinical stage of HIV. The 
initiation of ART is based on the clinical stage and the CD4 count is used to guide 
treatment and follow-up. The lack of a CD4 result should not delay the initiation of ART 
if the patient is clinically eligible according to the WHO clinical staging, but a CD4 test 
should be done as soon as possible.  
It is recommended not to start ART in the presence of an active OI. In general, 
OIs should be treated or stabilized before commencing ART. 
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 The following are the current NACO guidelines (2007) to start HAART in adults 
 Offer ART to symptomatic patients if the CD4 count is 200–350 cells/mm3. 
 Consider ART for asymptomatic patients with CD4 count between 200-350 
cells/mm3 and monitor closely for new symptoms. 
 If the CD4 count is 200–250 cells/mm3, physicians can consider repeating the 
CD4 test in 4 weeks in asymptomatic patients. This is to rule out the possibility of 
a 20% margin of error in laboratory results. 
 Patients should start ART before the CD4 count drops below 200 cells/mm3. 
 
Currently, the national programme provides the following combinations for first-line 
regimens 
 Stavudine (30 mg) + Lamivudine (150 mg) + Nevirapine (200 mg) OR Efavirenz 
(600 mg) 
 Zidovudine (300 mg) + Lamivudine (150 mg) + Nevirapine (200 mg) OR 
Efavirenz (600 mg) 
 
 
Principles for selecting the first-line regimen 
1. Choose 3TC (lamivudine) in all regimens 
2. Choose one NRTI to combine with 3TC (AZT or d4T) 
3. Choose one NNRTI (NVP or EFV) 
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Incidence of treatment failure on ART: 
 
As the number of people with HIV/AIDS on anti-retroviral therapy is on the rise, 
the numbers with treatment failure will also rise.  The resulting virologic failure 
diminishes the potential for long-term clinical success. This proves to be a major 
problem, at both individual level and as a public health concern. Drug-resistant strains of 
HIV selected through ongoing replication in the presence of ART also can be transmitted 
to uninfected or drug-naive patients, leaving them with fewer treatment options [7].  
In Uganda, Weidle et al. have reported phenotypic drug resistance as high as 36% 
in patients in the highly active ART program [8].  Dragsted and others reported an 
incidence of treatment failure at 12 months in their study group as 11.6 per 100 person-
years of follow-up [9].  The cumulative incidence of treatment failure in a cohort of 1370 
adult patients in a study  from the largest public HIV care centre in India was 3.9% (95% 
CI 2.9 to 4.9) [10].   
Inspite of the variation in the percentage of treatment failure on ART(largely due 
to the population characteristics, lack of standardised definitions for treatment failure 
among various studies), it is pertinent to understand that the problem of treatment failure 
is real and growing.  Also high cost, deficiency of reliable laboratory facilities, and 
inadequately trained personnel prohibit the assessment of treatment failure by viral load 
monitoring in resource-limited settings. 
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Possible risk factors for treatment failure with ART: 
 
Various risk factors for treatment failure with ART have been studied. 
To list a few,  
1. Poor adherence to medications/Missed visits  
2. Prior virologic failure in previously treated patient  
3. Higher baseline HIV RNA measurement (viral load) 
4. Lower CD4 cell count at baseline  
5. Younger age 
However, there are several other factors that need consideration as they could have an 
implication in the development of resistance to ART such as 
i) Pharmacokinetics  
ii) Resistant strains of the virus in the population 
 
1. Poor adherence to Medication: 
Adherence to medications is probably the most important factor predicting ART 
success. This has been shown repeatedly in various studies. [11] [12] [13] [5] [14] [15]. 
Adherence to ART also plays an important role in viral load suppression and 
immunological reconstitution. Studies have established that Antiretroviral adherence is a 
strong predictor of progression to AIDS and [16]death, next only to CD4 count [17] [18] 
[16]. Even though adherence has been predicted as the important factor of long term 
virological suppression, it has been shown in various studies that adherence to ART is 
only 70%, in spite of the fact long term suppression requires near–perfect adherence. [13] 
[19-20].  
14 
 
Though adherence is consider as the important factor, the tools used for 
adherence and health care professional who uses these stools are still unskilled in 
assessing medication adherence [5, 13, 21]. Non-adherence to ART, likewise, is common 
in all groups of treated individuals. The average rate of adherence varies by the method 
used to assess it and the group studied, but appears to be approximately 70%. For 
example, in a prospective study, 140 individuals in a public hospital HIV clinic were 
followed for 1 year after initiation of ART. The investigators assessed adherence using 3 
methods: a computer chip embedded in a specially designed pill-bottle cap to record the 
time and duration of each bottle opening (microelectronic monitoring system [MEMS], 
or MEMS caps), pill count, and self-report  [20]. They calculated a composite adherence 
rate including all 3 measures that demonstrated a mean adherence rate of 71%. Only 6% 
of the patients took >=95% of their medications, the optimal level for durable virologic 
and clinical success. 
Adherence measurements can be grouped into measures based on a patient's self-
report of pill-taking behaviour and measures that are objective surrogates of pill-taking 
behaviour, such as pill count or MEMS caps. While it is difficult to compare studies 
using different measures of adherence, mean adherence was suboptimal in the following 
disparate groups of HIV-positive individuals: in a large multicenter clinical trial (85% 
adherence by self-report), [22] among patients from a veterans and university hospital 
(75% by MEMS), [13] among the marginally housed (89% by self-report, 73% by pill 
count, 67% by MEMS), [23] among those with serious mental illness (66% by MEMS), 
[24] among predominately minority women (64% by MEMS), [25] and among 2 
different groups of inner-city residents with a history of injection drug use (80% by pill 
count, 53.5% by MEMS in one group, [26] and 78% by self-report, 53% by MEMS in 
the other group [27]. 
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Predictors of Adherence: 
A number of factors have been associated with non-adherence to ART. 
Understanding these factors can increase a clinician's attention to adherence when 
working with particularly susceptible patients and can inform the development of 
interventions to improve adherence. 
Several excellent reviews addressing the predictors of adherence have been 
published [28] [29]. As described by Reiter and by Ickovics et al in separate publications, 
the factors associated with medication adherence are commonly divided into 5 
intersecting categories [29]. 
1. Patient characteristics 
2. Treatment Regimen 
3. Disease Characteristics 
4. Patient-Provider Relationship 
5. Clinical Setting 
                       Patient characteristics is broad terminology, which includes wide range of 
features from socio-demographic  profile (like age, gender, economic status, educational 
status, etc) to psychological factors (knowledge about the disease and treatment, 
depression, attitude of the family members, pre-existing psychological morbidity 
present). There is paucity of data addressing each and every characteristic but there are 
few good reviews. [20] [13] [22] [14] [30] [12] [31] [32].  
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Though association between the socio-demographic profile and adherence is conflicting 
when the association is found between the few characteristics it is consistent. The 
following characteristics are repeatedly associated with the poor rate of adherence  
i. Low socioeconomic status 
ii. Low literary status 
iii. Unstable housing 
iv. Race/ethnicity 
The factors that are surprisingly are not consistent are gender, educational status 
and insurance status. This can be explained because most of the studies were done in 
developed countries but in developing countries like India where there exists a strong 
bias towards gender & literacy, one would expect conflicting results from that described.  
Psychological factors have profound influence on the adherence to medications. 
Though the disease itself can cause psychological manifestations this again adds to the 
pre-existing morbidity.  The features more consistently found to associated are 
depression, pre-existing psychiatric disease, alcohol dependence or drug abuse and more  
stressful lifestyle. 
  Treatment in HIV infection has evolved from monotherapy to combination 
therapy over the last decade. There has been a uniform use of CD4 counts for the 
initiation of ART. The factors that could possibly influence the treatment characteristics 
included the number of pills prescribed, the complexity of the regimen, the specific type 
of antiretroviral drugs, and the short- and long-term medication side effects. Of the above 
mentioned features, only number of pill usage has been consistently associated with poor 
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adherence even when the other factors are fulfilled. The specific type of pill used did not 
show any significant association with adherence. 
The disease characteristics include the stage of the HIV infection, duration of the 
infection, presence or absence of opportunistic infection and HIV related symptoms. Few 
studies describe poor adherence with a low CD4 cell count, and more adherence in the 
presence of opportunistic infection. Though the evidence is conflicting because most of 
the opportunistic infection are seen in patient with low CD4 cell counts, it can be 
postulated opportunistic infection adversely affect the patient daily activities where as 
CD4 count is the laboratory parameter.  The duration of illness alone is difficult to study 
because of longer the duration of illness more the influence of other factors. The duration 
of illness didn’t show any consistent association between adherences.  
Patient-provider relationship is important for treatment for any chronic diseases. 
This factor has been extensively studied and documented in western literature whereas in 
our country these features are less studied and largely underestimated. Given the fact that 
a patient has the autonomy to choose what suits him/her the best  for his/her condition, 
the characteristics that may affect adherence include the patient's overall satisfaction and 
trust in the provider and clinic staff, the patient's opinion of the provider's competence, 
the provider's willingness to include the patient in the decision-making processes, the 
affective tone of the relationship (warmth, openness, cooperation, etc), the concordance 
of race/ethnicity between patient and provider, and the adequacy of referrals. 
In India there are around 226 ART centres which distribute free ART to 280,954 
patients [5]. The prevalence of HIV infection is around 2.5 million. Though the exact 
data of the people living below CD4 cell count below 200 is not known it would be 
considerably higher. One reason for the lack of initiation and subsequently adherence is 
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the access to health care centre. Access to the ART centre has great impact on adherence 
to the medication. The characteristics of the clinical settings that influences adherence are 
access to ongoing primary care, involvement in a dedicated adherence program, 
availability of transportation and childcare, pleasantness of the clinical environment, 
convenience in scheduling appointments, perceived confidentiality, and satisfaction with 
past experiences in the health care system.  The closer the ART centre, there is increased 
rate of adherence. Though we don’t have any substantial evidence to show in treatment 
of HIV infection, this factor has been extensively studied in other chronic clinical 
conditions. [33]. 
Measure of adherence: 
There are different techniques used in research methodology to measure adherence. But 
applying this in clinical setting is difficult. In resource poor setting this becomes quite 
challenging to the team of therapist. [20] [13] [34]. The following are some of the 
measure used to measure adherence 
i. Pill count 
ii. Medication Event Monitoring System (MEMS) cap 
iii. Serological markers-plasma viral load, CD4 cell count 
iv. Hospital visit data 
Ensuring adherence is not the work of a single physician.  rather it is team work 
consisting of physician, nurses, pharmacist, counsellors, and other health care individual. 
Accurately assessing adherence requires clinicians to develop a collaborative and 
nonjudgmental relationship with patients. The key to asking patients about their 
adherence is not in the specifics of the tool used but in taking the time to ask about 
adherence regularly, and doing so in an open and truly inquisitive manner. Otherwise, 
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many patients will simply state what they believe the clinician wants to hear: that they 
have been perfectly adherent. 
In conclusion, improving adherence requires a combination of methods appropriate to the 
patient and clinical setting. Certain modifiable factors that influence adherence include 
depression, substance abuse, homelessness, and the therapeutic relationship between 
patient and provider should be addressed in a proactive and ongoing manner. Measures to 
improve adherence includes dedicated educational and collaborative time with every 
patient to plan for medication adherence and to maintain necessary support and 
collaboration throughout the course of treatment. This combined approach would address 
the entire spectrum of problems that varies commencing side effects dealt with, 
medications simplified or changed if necessary, and adherence devices supplied where 
appropriate. Adherence is the responsibility of the clinical team which occupies a higher 
rank in ART therapy. What is probably required, however, is a commitment to ask about 
and support medication adherence regularly in an open, nonjudgmental, and collaborative 
manner. 
2. Prior virological failure 
World health organization (WHO) defines treatment failure of either a decrease in CD4 
count to the baseline or below, or a 50% decrease from the on-treatment peak value (if 
known), or CD4 concentrations persistently less than 100 cells/ml. [35]. Prior virological 
failure has more influence on the current treatment because of resistance of the virus, 
need of second line anti-retroviral agents for anticipated virological suppression, increase 
in adverse drug reaction, high cost, more hospital visits and poor adherence.   
Research is needed to identify whether intensive patient education, with targeting 
of high-risk groups, can maximize the success of HAART in real-world practice. Future 
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studies of antiretroviral agents should address sex differences in pharmacodynamics and 
adverse drug reactions. [36] [37]. Poor viral load suppression is associated with higher 
rate of opportunistic infection. 
3. Higher baseline HIV RNA measurement 
High baseline HIV RNA has been shown be one of the predictors of treatment 
failure. But the association is not strong.  In some, there is poor or no correlation with 
the high viral RNA load and treatment failure. Though it is theoretical for one to assume 
this it is not true because patient with high viral RNA load are more often symptomatic 
and have good adherence to treatment. In trials involving those patients there tend to be 
more bias because of the close follows up of these patients as compared to those with 
low viral RNA load.  
High viral load indirectly indicates virulence of the virus to overcome the host 
immune system, chronicity of the infection, and poor host immune defence mechanism. 
The immune system of the host is destroyed thoroughly predisposing the host to the 
opportunistic infection which increase the mortality and morbidity associated with HIV 
infection. The high viral RNA load is associated with treatment failure though the 
association is not too strong it will be wise to start ART and suppress the viral RNA load 
because the longer the duration of the patient with increase in viral RNA more the 
complication rate. [38] 
4. Lower CD4 cell count 
Low CD4 cell count is associated with treatment failure and development of 
resistance. In a study done by Deek et al, they showed the there is an increase in the 
resistance when protease inhibitor is used with low CD4 cell count. There aren’t any 
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subsequent studies showing the relationship of combination therapy and low CD4 cell 
count in treatment failure. However the combined data from different studies predicted 
that low CD4 cell count is associated with treatment failure. The reason for this is 
multiple like increased risk of opportunistic infection, increased chance of immune 
reconstitution inflammatory syndrome, development of resistance to the baseline anti-
retroviral agent and generally theses patient are malnourished. [38] 
5. Other factors 
There are a number of other factors that influence the treatment outcome in ART. 
But these factors have not consistently or measurably shown to be predictors of treatment 
outcome. The factors associated are older age, poor socioeconomic status 
(independently), other chronic medical condition, educational qualifications, occupation, 
social status etc,. These factors both independently and also together influence the 
treatment. It is difficult to study each of these factors independently but studies show that 
these factors individually affect the treatment outcome.  
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Antiretroviral therapy  absorption: 
 
 
Pharmacokinetic implications 
 
 
The use of multidrug antiretroviral therapy for HIV-infected patients, and the 
need for these patients to receive multiple concomitant drugs for either the treatment of 
opportunistic infections or the management of drug-related adverse events, makes it 
imperative to understand the pharmacokinetics of all the drugs in the regimen as well as 
the possible implications on development of resistance. Inter-patient variability in drug 
absorption, distribution, metabolism and excretion can all contribute to variability in 
plasma drug concentrations.[39].  
Protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
are primarily metabolised by the cytochrome P450 (CYP450) enzyme family. Any drug 
that acts as an inhibitor or inducer of the CYP450 system can cause significant change in 
plasma drug concentrations.[40] 
 
 
Anti-retroviral drug malabsorption: 
 
Diarrhea and resistance 
 
A study from Brazil found that one or more antiretroviral drugs are malabsorbed 
in virtually all patients with diarrhoea and wasting, assessed in this setting by plasma 
levels of the drugs. Furthermore genotypic testing revealed that viral resistance to the 
drugs being malabsorbed is often associated [41]. This study also demonstrated that 
addition of alanyl-glutamine and glutamine in treating diarrhoea may help to improve 
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therapy for patients with AIDS who have diarrhoea and/or wasting in developing, 
tropical areas. 
 
 
 
Role of Therapeutic drug monitoring 
 
 
The introduction of TDM represents a major step in the way to optimize 
antiretroviral therapy for each individual. Firstly, it can improve the response to 
treatment by just modifying drug doses. There is no doubt that the integrated use of TDM 
and drug resistance testing will result in a significant improvement in the management of 
antiretroviral therapy. 
Secondly, an important application of TDM concerns the adherence issue. This aim 
should be used cautiously because serum concentrations may reflect drugs administered 
within the past 24 hours but say nothing about medications taken days or weeks before 
blood sample collection. 
Monitoring hair levels has been proposed as a good method to assess past adherence 
based on the continued growth of the hair and the accumulation 
of the drug in this tissue. 
Thirdly, TDM also seems to be of great utility to detect drug-drug and drug-food 
interactions and malabsorption problems, and could allow dose adjustment in order to 
maintain effective plasma concentrations. 
However, more studies are necessary to determine a therapeutic range in which plasma 
drug concentrations need to be kept. The recognition of toxic and suboptimal drug 
concentrations needs to be established for each compound. Controlled-concentration 
therapy seems to be the most appropriate strategy to maintain serum drug concentrations 
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much higher than the IC95 for each drug. There is a need for a reliable estimation of the 
IC90 for wild type as well as mutant HIV strains. 
Fourthly, PIs and NNRTIs are the most appropriate candidates for TDM. The 
applicability is still unclear for NRTIs, since they need to be intracellularly 
phosphorilated to become active. 
Finally, the additional costs of TDM as part of clinical routine exams need to be 
balanced against an expected reduction in pharmaceutical costs. Dose individualization 
needs to be pursued in each individual for providing an effective drug concentration. This 
represents a more rational use of antiretroviral drugs and might prevent therapeutic 
failure due to low plasma drug concentrations.[42] 
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Drug resistance  
 
Resistance to ARVs results from mutations in the protease and reverse transcriptase 
genes of the virus. HIV has a rapid turnover with 10
8
 replications occurring per day. The 
error rate is high, resulting in genetic diversity within the population of virus in an 
individual. This mixture will include drug-resistant mutants. When drugs only partially 
inhibit virus replication there will be a selection pressure for the emergence of drug-
resistant strains. The rate at which resistance develops depends on the frequency of pre-
existing variants and the number of mutations required. Resistance to zidovudine occurs 
with an accumulation of mutations, whilst a single-point mutation will confer high-level 
resistance to all three NNRTIs.  
 
HIV antiretroviral drug resistance testing has become routine clinical management of the 
HIV patient. Genotypic assays to determine the genetic structure of the RT and protease 
genes of HIV are available. The tests are based on PCR amplification of virus and give 
an indirect measure of drug susceptibility in the predominant variants. Such assays are 
limited both by the starting concentration of virus, most assays requiring at least 1000 
copies/mL of blood, and by their poor ability to detect minority strains. For results to be 
useful, samples must be analysed when the patient is on therapy, as once the selection 
pressure of therapy is withdrawn, wild type virus becomes the predominant strain and 
resistance mutations present earlier may no longer be detectable.  
The use of genotypic assays with appropriate interpretation in patients for whom therapy 
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is failing has shown significant virological benefits. Phenotypic assays provide a more 
direct measure of susceptibility but the complexity of the assays limits availability and no 
additional advantage has been demonstrated. In the UK, increasing numbers of patients 
are infected with viral strains originating in sub-Saharan Africa, which may require 
modification of the assay and the interpretation of the results.  
 
There is evidence for the transmission of HIV strains that are resistant to all or some 
classes of drugs. Studies of primary HIV infection have shown prevalence rates between 
2-20%. Prevalence of primary mutations associated with drug resistance in chronically 
infected patients not on treatment ranges from 3% to 10% in various studies.  
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MATERIALS AND METHODS 
 
 
 
Study design 
 
The study is a matched case-control study from the cohort of patients attending HIV/ID 
clinic in Christian Medical College, Vellore during the period January 2000 to August 
2009. 
CMC Vellore is a 2200 bedded tertiary care, multispecialty teaching hospital in 
Southern India. It caters to patients from all over India. The first case of HIV infection in 
India was diagnosed here in the Department of Clinical Virology in 1986 and since then, 
the Department of Medicine-I and Infectious Diseases has been actively involved in HIV 
clinical care and treatment. At present the Infectious Diseases department has been taking 
care of all the complex HIV and infectious diseases related problems. Every PLWHA 
after being started on ART, is transferred to our Infectious Disease (ID) clinic which 
exclusively caters to HIV patients though they are also seen in our routine infectious 
disease referral clinics as well.  
The ID clinic is an interdisciplinary clinic run by the departments of Medicine, 
Paediatrics, Obstetrics and Gynaecology, Dermatology and STD and Psychiatry. It also 
includes 3 well trained and experienced counsellors and pharmacists. The annual out-
patient load of our ID clinic is around 3000 patients, apart from the cases seen in our 
NACO ART centre and referral clinics. The Clinical Virology Department at CMC 
Vellore is a national reference laboratory centre for HIV testing. The hospital has a well-
developed system for infection control and exposure prevention and has instituted a 
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comprehensive HIV policy also providing post exposure prophylaxis to all its employees. 
From January 2000 till the end of August 2009, a total of 823 patients were on 
antiretroviral therapy and constituted the ID clinic cohort on follow-up. Of these, 116 
patients were on self-paid ART, while the rest i.e. 707 patients were initiated on free 
NACO ART. 178 patients on NACO ART were transferred out to other ART centres for 
closer follow-up (Tamil Nadu as well as other states in India). 
 
The generic ART comprised of a combination of two nucleoside reverse 
transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor 
(NNRTI). The NRTIs included Stavudine, Zidovudine and Lamvudine and the NNRTIs 
used were Nevirapine and Efavirenz. 
 
Case definition 
We defined cases as adults (age > 16 years) with documented treatment failure (defined 
as either clinical/immunological or virological failure as per criteria by WHO[43],[35]) 
from the above-mentioned cohort, who had been on ART for a minimum duration of 12 
months. 
We also defined treatment failure as follows 
Clinical failure - New or recurrent WHO stage 4 condition  
CD4 cell/Immunological failure defined as  
 Fall of CD4 count to pre-therapy baseline (or below); or 
 50% fall from the on-treatment peak value (if known); or 
 persistent CD4 levels below 100 cells/mm3 
Virological failure - Plasma viral load above 5,000copies/ml  
 
29 
 
 
Control selection 
Controls were age (+/- 5 years) & sex matched PLWHA on regular follow-up with us 
who were on ART for a similar duration (+/- 6months)   as the cases. Controls were 
selected in a non-random fashion from the cohort. Random selection was deemed 
unnecessary as it was a matched case-control study. We matched controls for possible 
confounders like duration of therapy, age and sex.  
 
 
Data collection 
 
Demographic and treatment details were noted on data information sheets using the data 
available from the Out-patient/In-patient records maintained by the Medical records 
department.  
 
Sample size 
Sample size was calculated based on a proportion of patients found to have treatment 
failure from a study done in Mumbai 
A cross-sectional study among HIV-infected patients who were receiving ART in 3 
private outpatient clinics in Mumbai from December 2004 through April 2005 had found 
that  22% of patient with suppressed virological load to be non-adherent, with an 
adjusted odd’s ratio 5.70 for an association with adherence>95% and virological 
suppression.[44] 
Using this data, sample size was calculated using Epi-Info ver6 statscal and we found 
that a sample size of 42 in each group would have 95% power with alpha-error of 0.05.  
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Statistical analysis 
 
SPSS ver.13 was the software used for data entry and statistical analysis. 
For normally distributed continuous variables, independent two sample t-test was used to 
compare the means between the two study groups.  Chi-square test or fisher’s exact test 
was used to compare the categorical variables between the groups, as appropriate.  
 
To identify risk factors independently associated with treatment failure, variables found 
to be significantly different between cases and controls in the univariate analysis were 
entered into a logistic-regression model. A value of p<0.05 constituted a significant 
difference. Odds ratios and 95% CI were obtained. 
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RESULTS 
 
 
 
From January 2000 to August 2009, a total of 823 patients were on antiretroviral 
therapy and being followed up in our ID clinic. Of these,116 patients were on self-paid 
ART, while the rest i.e. 707 patients were on NACO ART. 178 patients on NACO ART 
had been transferred out to other ART centres(Tamil Nadu as well as other states). 66 
patients were identified as potential cases after carefully examining the case registry 
maintained in the pharmacy for anti-retroviral drugs, which works in conjunction with 
the ID clinic in CMC, Vellore.  However, 24 patients could not be enrolled in the study 
for data collection and analysis because of various reasons (incomplete data entry/charts 
disposed off/ no appropriate controls/Children). 
 
Baseline characteristics 
 
42 cases were considered appropriate for inclusion in the study and 42 controls were 
selected and matched for age, sex and duration of therapy.  
As defined by the WHO criteria for treatment failure, majority 33/42 (78.6%) had 
documented virological failure; and in those who couldn’t afford quantitative viral load, 
CD4 counts documented immunological failure.  A significant number of cases were 
detected early based only on virological failure 13/42(30.9%).There was evidence of 
clinical failure in 20/42(47.6%) of the total cases studied. 
Genetic susceptibility testing was performed in 21 out of the 33 cases who could afford 
viral loads. We found high-level resistance to NNRTIs (NVP/EFV) and 3TC/FTC in all 
of them (100%) whereas only 7 cases had high-level resistance to AZT/d4T or 
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Thymidine Associated Mutations (TAMS). Only two out of the 21 had triple mutations – 
mutations to NNRTIs/NRTIs and PIs. 
Majority of the cases were from outside Tamil Nadu 22/42 (52.4%) from Neighbouring 
states and 3/42 (7.1%) from the rest of India as compared to 10/42(23.8%) of controls. 
Most controls were from Tamil Nadu 32/42(76.2%) and in particular from in and around 
Vellore. The reason for this diverse geographic distribution was that most cases of 
treatment failure were referred patients to the CMC ID clinic for expert management 
whereas the controls were patients who had been enrolled under the NACO-ART 
programme and so tended to be locals. We did not match for geographic location as most 
of the patients seen in our ID clinic were referred to their closest ART centre.  
All cases and controls were diagnosed to be HIV infected according to guidelines 
provided by the NACO algorithms for diagnosis of HIV infection.  
None of the cases or controls in the study population were co-infected with Hepatitis B 
Virus (HBV) or Hepatitis C Virus (HCV). None tested were VDRL positive. 
The risk factor for acquisition of HIV among the cases was predominantly heterosexual 
intercourse. Among the controls again the predominant route was heterosexual 
intercourse but homosexual contact and blood transfusion contributed to one each. 
Information on spouse testing for HIV was not available in majority of the cases.  
Among the controls (on whom the data was available i.e. 50%) 2/3
rd 
of the spouses
 
were 
negative for HIV infection i.e. were discordant couples.  
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WHO clinical stage prior to treatment: 
 
 
WHO clinical staging prior to therapy was also studied.  
 
Nine (21.4%) cases as compared to 3(7.2%) controls belonged to Clinical Stages 1 and 2.  
Thirty three (78.6%) cases as compared to 39(92.9%) controls belonged to Clinical 
Stages 3 and 4. There was no statistically significant difference between the two groups. 
 
Pre-ART Opportunistic Infections (Pre-ART OIs) : 
 
Twenty-seven (64.3%) of cases had a documented opportunistic infections prior to the 
initiation of ART, as compared to twenty-five (59.5%) of controls, which was not 
statistically significant. Of these, eight each of the cases and controls with documented 
opportunistic infections had multiple OIs. There was no statistically significant 
difference between the two groups with regard to the incidence of various OIs.  
Between the two groups,18 Cases were found to have Mycobacterial OIs compared to 15 
in controls. Mycobacterial infections were the commonest OIs among this study 
population. 10 Cases were documented to have Candidial OIs  compared to 14 controls. 2 
cases and 2 controls were found to have Pneumocystis carinii pneumonia. 2 cases had 
CMV infections, while no control patient was documented to have CMV infection. One 
control was found to have cryptococcal OI, when no case was found to have cryptococcal 
infection. 2 Cases were diagnosed with Cryptosporidial diarrhoea  prior to ART 
compared to 1 control. 
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Table no. 1 
Pre-ART opportunistic infections compared in both the group 
Opportunistic infection Cases Controls p-value 
 
Pre-ART OIs 
   
             YES 27(64.3%) 25(59.5%) 0.65 
 Multiple OIs (>1)                 
              YES 8(19.1%) 8(19.1%) 1.00 
Type of Infection    
 Mycobacterial 18(42.9%) 15(35.7%) 0.50 
 Candidial    10(23.8%)    14(33.3%)      0.33 
 Pneumocystis carinii 2(4.8%) 2(4.8%) 1.00 
 CMV infection 2(4.8%) 0 0.15 
 Cryptosporidial infection  2(4.8%) 1(2.4%) 0.55 
 
 
 
 
 
 
 
 
LABORATORY PARAMETERS 
 
 
Various baseline laboratory parameters were compared between the two  study 
populations and there was no statistically significant difference. [Ref Table 2] 
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Table 2 
Baseline characteristics of Study Population 
Parameter Cases 
n-42 
Controls 
 n-42 
p-
Value 
Matching Criteria    
Age, mean in yrs(S.D.) 43.5(+/-7.7) 42.3(+/-6.9)  
Sex, M/F 31/11 31/11  
Duration of therapy(in months)  38.8(+/-24.9) 39.1(+/-22.7)  
Baseline Characteristics    
WHO Clinical Staging 
               Stages 1 & 2 
               Stages 3 & 4 
 
9(21.4%) 
33(78.6%) 
 
3(7.2%) 
39(92.9%) 
    0.06 
Pre-ART OIs 
     Documented Pre-ART OIs 
   
18(64.3%) 
   
19(59.5%) 
     
    0.82 
     Multiple Pre-ART OIs 9(33.3%) 6(24%) 0.39 
Laboratory Parameters 
       Hemoglobin (g/dl) 
         Total WBC count(per cu.mm) 
         ALC(per cu.mm) 
        AEC(per cu.mm) 
         Total serum protein (g/dl) 
         Serum Albumin (g/dl) 
         SGOT (IU/L) 
         SGPT (IU/L) 
         Baseline CD4 count*(cells/cu.mm) 
 
11.15(+/-2.49) 
6190.48(+/-
3085.27) 
1557.0(+/-1052.31) 
285.76(+/-44.09) 
8.264(+/-1.03) 
3.714(+/-0.70) 
48.40(+/-41.89) 
47.69(+/-50.08) 
122.17(+/-138.91) 
 
11.68(+/-2.05) 
6483.33(+/-3083.31) 
1588.14(+/-860.41) 
430.95(+/-66.49) 
8.300(+/-1.00) 
3.581(+/-0.74) 
45.55(+/-54.80) 
36.48(+/-32.74) 
125.32(+/-75.64) 
 
0.288 
0.665 
0.882 
0.434 
0.873 
0.399 
0.789 
0.228 
0.901 
    
*missing data – Cases(n=35), Controls(n=41) 
ALC – Absolute lymphocyte count, AEC – Absolute eosinophil count 
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Genotypic drug resistance testing: 
 
Genotypic drug resistance testing was available on 21 cases (50%). 
All of the twenty-one patients were found to have High-level resistance to NNRTIs. The 
most common mutations were Y181C, K103N, V106M, V108I and L234I. 
Seven out of the 21 had high-level resistance to NRTIs, while all the 21 had significant 
mutations conferring resistance to Lamivudine/Emtricitabine. The most common 
mutations were M184V, D67N, K70E, V75M and M41L. 
Only two of these patients had mutations to Protease inhibitors, and both were resistant 
to NNRTIs and NRTIs. 
 
 
Type of ART regimen & ART centre for Initial drugs: 
 
Type of ART regimen was different in both the study groups. 18 cases (42.9%) 
were started on a combination of d4T/3TC/NVP or EFV, as compared to 28 controls 
(66.7%). 15 cases (35.7%) had AZT/3TC/NVP or EFV as the initial regimen, as 
compared to 13 controls (31.0%). One case and a control each were on TDF/FTC/EFV 
regimen. 8 cases were started on other regimens, mainly dual therapy. No case or control 
had PI-based regimen as the initial choice of ART. 
 
30 cases (71.4%) were paying for their ART medications as compared to 3(7.14%) 
controls. Since the NACO ART centre at CMC Vellore was started in April 2008, this 
reflects a probable selection bias as most of the controls selected were being followed up 
here. 
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Pie chart 1(ART regimen in Cases) & 2(ART regimen in Controls) 
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Risk  factors :    UNIVARIATE  ANALYSIS 
A series of putative factors were analysed. Odd’s ratios were calculated with  measures 
of significance (p-values). 
 
A.  NON-COMPLIANCE 
Non compliance to therapy was divided into two specific categories 
(a) Non- adherence 
(b) Unstructured treatment interruptions 
 
 
NON-ADHERENCE 
 
Adherence was reported by patients themselves. Patients were asked about the number of 
pills missed and their pill-diary was examined to calculate the proportion of pills taken. 
All cases and controls had self-reported adherence of more than 80%.  Adherence less 
than 95% was reported in 10 cases (23.8%) and one control (2.4%). 
Odds ratio for non-adherence (<95%) associated with treatment failure was 12.81(95%CI 
1.54 – 281.45) with a p-Value of 0.004, suggesting statistical significance.  
Table no. 3 
Adherence among cases & controls 
Self-reported 
Adherence 
 
Total Cases Controls 
 >95% 32 41 73 
% within Case/Ctrl 76.2% 97.6% 86.9% 
80-95% 10 1 11 
% within Case/Ctrl 23.8% 2.4% 13.1% 
 Total Count 42 42 84 
% within Case/Ctrl 100.0% 100.0% 100.0% 
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UNSTRUCTURED TREATMENT INTERRUPTIONS  
 
Interruptions in treatment schedules (as brief as 10days), in otherwise adherent patients 
was also associated with treatment failure. These treatment interruptions were largely 
unstructured. It was either physician advised (in view of serious drug toxicity) or self-
imposed by patient (various social reasons – intercurrent illness/fasting/inability to 
procure medications etc.). Seven cases (16.66%) had treatment interruptions due to any 
of the above reasons on a background of usual good self-reported adherence. Interrupted 
treatment was analysed as a risk factor for treatment failure and odds ratios calculated 
were found to be statistically significant i.e.  9.56(95%CI 1.11 to 213.35), p-Value of 
0.0137 .  
 
When treatment interruptions were combined with non adherence,    OR 27.88(95% 
CI 3.50 to 596.37) with p-Value of 0.00002 was significantly associated with treatment 
failure.   
   Table 4 
Interrupted Treatment excluding poor  adherence 
   Case1/Ctrl2 
Total    1 2 
 YES 7 0 7 
% within Case1/Ctrl2 16.7% 0.0% 8.33% 
NO 35 42 77 
% within Case1/Ctrl2 83.3% 100% 91.6% 
Total Count 42 42 84 
% within Case1/Ctrl2 100.0% 100.0% 100.0% 
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B. Past inappropriate therapies (PIT)  
 
Improper regimens (e.g., dual regimens) and inadequate drug dosing were both 
identified as Past inappropriate therapies. Use of dual therapy in the past was identified 
as a potential risk factor for failure in  7(16.7%)of the 42 cases, 1(2.4% ) out of the 42 
controls. One of the cases was also noted to have received sub-optimal doses of anti-
retroviral therapy in the past. PIT was significantly associated with treatment failure. [OR 
9.65 (95%CI 1.12 to 215.94), p-Value of 0.0135]. 
 
 
 
C. Diarrhoea  
 
Presence of prolonged diarrhoea was defined as increased stool frequency or a 
change in stool consistency to a liquid state either continuously or in episodes). Twelve 
cases (28.6%) had a history of prolonged diarrhoea (more than one month) after the 
diagnosis of HIV infection, compared to one control (2.4%). This association was 
statistically significant. [OR 16.40(95%CI 2.02 – 355.96) p-Value of 0.0009]  
 
 
 
D. GI opportunistic infections – prior to and after initiation of ART: 
 
Eight Cases (19.4%) had documented GI opportunistic infections compared to 
none among the controls. Documentation of a GI opportunistic infection both prior to and 
after initiation of ART was significantly associated with treatment failure.[OR 
11.06(95%CI 1.31 – 244.27) ; p-Value = 0.007] 
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E. Medical Co-morbidities: 
Several medical co-morbidities including diabetes, hypertension, dyslipidemia, renal 
failure, alcoholism and other diseases such as Ischemic heart disease, Seizure disorder, 
Chronic Obstructive Pulmonary Disease etc. were compared between the two groups.  
Presence of medical co-morbidity (p= 0.53) or any particular co-morbidity were not 
significantly associated with treatment failure (refer Table no.5) 
Table no 5.  
Comorbidities between the two groups 
Parameter studied Odd’s ratio(95%CI) p-Value 
Diabetes mellitus 0.37(0.05 – 2.36) 1.40 
Hypertension 0.38(0.07 – 1.84) 1.79 
Dyslipidemia 3.33(0.55 – 25.68) 0.13 
Alcoholism 1.00(0.0 – 38.11) 1.00 
Renal failure 2.05(0.14 – 59.43) 0.55 
Other medical co-morbidities 3.00(0.92 – 10.15) 0.04 
 
 
F. Use of other medications that could have possible interactions: 
 
Information on other medications that patients have been on, were looked at for potential 
interactions with anti-retroviral therapy leading to possible sub therapeutic levels of the 
antiretrovirals. The following drugs with likely drug-interactions were identified:  
Antiepileptics (Phenytoin/Phenobarbitone/Valproate/Gabapentin),  
Anti-diabetic drugs(Glipizide/Metformin), Statins/Fibrates,  
Anti-hypertensives ( Amlodipine/Hydrochlorthiazide), 
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Anti-depressants (Amitryptilline/Sertraline),  
GI drugs( Pantoprazole/Domperidone). 
Drug interactions between ART and other drugs were not  associated with treatment 
failure. [OR 1.15 (95%CI  0.37 - 3.59),p-Value 0.79] 
 
 
G. Drug toxicity: 
 
Drug toxicity or an adverse drug reaction to antiretrovirals or other drugs used in 
treatment of HIV infection were also studied for a possible impact on treatment failure 
with ART as they often require a modification of the ART regimen. 16 (38.1%) cases 
had experienced ADR as compared to 6 controls (14.3%). 
Table no 6 
Adverse Drug reactions (ADR) compared between both the groups 
Adverse Drug Reaction Cases Controls p-value 
 
Presence of Drug Toxicity 
   
             YES 16(38.1%) 6(14.3%) 0.013 
 Multiple ADR (>1)                 
              YES 4(9.5%) 0 0.04 
Type of Drug Toxicity    
 Skin Rash 6(14.3%) 0 0.011 
 Anemia      4(9.5%)      1(2.4%)      0.16 
 Neuropathy 2(4.8%) 1(2.4%) 0.55 
 Lipodystrophy 6(14.3%) 1(2.4%) 0.046 
 Metabolic  
(Diabetes/Dyslipidemia)  
2(4.8%) 3(7.14%) 0.64 
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Six (14.3%) cases developed drug rash, either to NVP or cotrimoxazole as compared to 
none among the controls. Six (14.3%) cases also had lipodystrophy as compared to one 
among the controls (2.4%). Four (9.4%) cases developed anaemia as compared to one 
among the controls. Two (4.7%) cases reported neuropathy compared to one control 
(2.4%). There were metabolic complications (diabetes/dyslipidemia) in 2 (4.7%) cases 
and 3 controls (7.14%). Four cases had more than one ADR compared to none in the 
controls. 
Overall, drug toxicity was significantly associated with treatment failure. 
[OR 3.69(95%CI 1.15 to 12.35); p-Value = 0.013]. 
 
We did not find severe drug toxicities like lactic acidosis, hepatitis and pancreatitis in our 
study population, which usually require stoppage or modification of the ART regimen.   
Serious drug toxicities(in our study – Skin Rash) were found to be significantly 
associated with treatment failure however the CI was very wide. [OR 8.14 (95% CI 0.93  
to 184.15) ; p-Value = 0.028].  
 
 
 
H. Occurrence of Immune reconstitution syndrome (IRIS): 
 
  Four cases and 3 controls were documented to have IRIS after initiation of 
ART. Occurrence of IRIS had no significant association with treatment failure. IRIS 
documented among the cases were tuberculosis in 2,   cryptococcal meningitis and 
disseminated MAC infection in one each. 
Granulomatous prostatitis, Genito-urinary TB and Tuberculous meningitis were the 
diseases presenting as IRIS among the controls. 
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Univariate analysis identified the following variables to be significantly associated with 
treatment failure. 
 Non-adherence 
 Treatment interruptions in compliant patients 
 Past inappropriate therapy 
 GI opportunistic infections 
 Diarrhoea 
 Drug toxicity 
 
 
Table 7 
Summary of Risk factors on Univariate analysis 
Risk Factor Odd’s ratio(95%CI) p-Value 
Non-adherence 
(Self-reported adherence<95%) 
12.81(1.54 – 281.45) 0.004  
Treatment Interruptions, 
Excluding non-adherence 
9.56(1.11 - 213.35) 0.014  
Past inappropriate therapies  9.65(1.12- 215.94) 0.014  
Diarrhea 
Gastro-intestinal OIs 
16.40(2.02 – 355.96) 
11.06(1.31 – 244.27) 
0.0009 
0.007 
 
Use of drugs with possible  
interactions 
 Drug toxicity 
1.15 (0.37 - 3.59) 
 
3.69(1.15 - 12.35) 
0.79 
 
0.013 
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MULTIVARIATE  ANALYSIS -  LOGISTIC  REGRESSION 
 
 
The above variables were subjected to a Multivariate analysis, which incorporated these 
variables in a step-wise logistic-regression model. Non-adherence, drug toxicity and 
diarrhoea were identified as significant risk factors for treatment failure. 
 
 
 
Table 8 
Summary of Risk factors on Multivariate analysis 
(Logistic regression model) 
Risk Factor Odd’s ratio(95%CI) p-Value 
Non-adherence 
(Self-reported adherence<95%) 
15.46 (1.55 – 154.08) 
 
0.02  
Documented drug toxicity 4.13 (1.095 – 15.534) 0.036  
    
Diarrhea 
 
23.446 (2.572 – 213.70) 0.005 
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DISCUSSION 
 
 
 
The purpose of this case-control study was to evaluate the potential risk factors 
that could predict treatment failure. By identifying the population at risk for treatment 
failure, targeted disease management interventions can be undertaken to improve 
outcomes of ART.  
 
A study published from Treat Asia HIV Observational Database(TAHOD) 
reported 45 patients out of 1846 i.e. 2.43% stopping their first regimen due to treatment 
failure, with a median treatment duration of 1.2 years. In comparison, the cumulative 
incidence of treatment failure in a cohort of 1370 adult patients in a study from the 
largest public HIV care centre in India was 3.9% (95% CI 2.9 to 4.9) [10]. 
 
A good proportion of cases of treatment failure in our study (30.9%) were 
detected early by means of quantitative PCRs for Viral RNA, which is offered to all 
patients who can afford the viral load testing, in our centre. There is evidence that in 
resource-limited settings as well, CD4 count and HIV RNA monitoring to guide 
switching to second-line ART improves survival and, under most conditions, is cost 
effective. About three-quarters of our cases i.e., 78.5% of the cases were diagnosed as 
treatment failure based on a quantitative HIV RNA PCR and a significant number of 
these (21/33) also had genotypic resistance testing done.  All the patients in whom 
genetic resistance testing was done, there was high-level resistance to NNRTIs 
(NVP/EFV) and NRTIs (3TC/FTC). The most common mutations found were Y181C, 
K103N & M184I/V, D67N, K70E, V75M and M41L. These findings are consistent with 
the findings from other studies in India and other developing countries [45-46]. A study 
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from Southern India which included 138 patients with treatment failure on generic first-
line ART found, that of the NRTI resistance mutations, M184V was the most common 
(79%). Thymidine analogue mutations (TAMS) including M41L, T215Y/F, L210W, 
D67N, K219E/Q and K70R were found in 60% of patients. In the same study, NNRTI 
resistance mutations were in 88% of the patients and included K103N, Y181C, and 
G190A[47]. However, drug resistance patterns in developed countries differ from that 
seen in our study, largely due to the difference in profile of first-line ART regimens 
being used (NNRTI-based Vs. PI-based[48]. 
 
Three variables were found to be significantly associated with treatment 
failure(after a logistic regression analysis) in our study, namely, Non-adherence as 
reported by the patients themselves, history of prolonged diarrhoea and drug toxicity to 
any antiretroviral drug or Cotrimoxazole.  
 
  Poor adherence was an important risk factor for treatment failure on ART [OR = 
15.46]. A retrospective longitudinal analysis of HIV-infected patients followed in the 
Massachusetts General Hospital found poor adherence as a risk  factor for treatment 
failure with HR of 3.44(95%CI:2.34 to 5.05). The degree of difference could possibly be 
explained by the fact that NNRTI based regimens tend to be unforgiving, as resistance 
develops sooner, and also that the levels of health literacy differ in developed and 
developing nations[32]. Our study provides further confirmation of adherence as an 
important determinant of subsequent treatment failure, and serves as a reminder of the 
importance of initial early investments in adherence counselling and support. This is 
probably the most effective way to maximize long-term treatment success in this 
population. The importance of adherence in the success of antiretroviral therapy has been 
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shown repeatedly in various studies. [11-15][5], even though the strength of this 
relationship may vary with different population sub-groups.  
 
Interruptions in treatment schedules (as brief as 10days to as long as 6months), in 
otherwise adherent patients may also be associated with treatment failure. In our study, 
treatment interruptions were largely unstructured. It was either physician advised (in 
view of serious drug toxicity) or due to patient-related problems (various social issues – 
intercurrent illness/presumed toxicity/inability to procure medications etc,.).  
 
Past inappropriate therapy (inappropriate schedule/inadequate drug dosing) is also 
a recognised risk factor for failure of anti-retroviral therapy, due to sub-optimal 
therapeutic levels to suppress viral replication resulting in emergence of resistance. Our 
study had a significant number of patients with a past history of initial dual therapy 
(16.6%) all started elsewhere, possibly due to lack of knowledge among the HIV care 
physicians or inaccessibility of specialist care. There is strong evidence that management 
of complex HIV and HAART related issues by a specialist physician leads to better 
patient outcomes [49-51]. The greater cost and lack of knowledge regarding the anti-
retroviral drugs prior to advent of the NACO-ART programme may also have 
contributed to initiation of inappropriate therapies by the General practitioners. 
 
There has been a growing concern over the possibility that many patients globally 
are experiencing virological failure despite high levels of adherence to generic NNRTI-
based HAART, a frequently used first line therapy in global antiretroviral (ARV) scale-
up efforts. This seeming discordance in adherence and virological response has prompted 
search for other possible risk factors. Chronic diarrhoea is one of the most common 
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symptoms of HIV/AIDS in resource-limited countries. It results in decreased quality of 
life, progressive wasting and nutrient deficiencies. It is also associated with increased 
early mortality in patients presenting for ART [52]. There is evidence that antiretroviral 
drugs are poorly absorbed in most patients with diarrhoea and wasting, and this may lead 
on to drug resistance, due to presence of sub-therapeutic serum drug levels for prolonged 
periods of time [41][53]. Altered gut motility (possibly due to increased parasympathetic 
drive) and defective absorption may also play a role in AIDS-related pathogen-negative 
diarrhoeas [53-54]. In our study, history of prolonged diarrhoea (documented in the 
chart) was identified as a risk factor for treatment failure [OR of 23.446]. In a developing 
nation, lack of proper food hygiene combined with poor sanitation and cultural practices 
may predispose immune-compromised individuals to frequent diarrhoeal illnesses and 
there-by contribute further to malnutrition and eventual poor outcomes. At present, there 
is a no clear data implicating diarrhoea as a predictor of treatment failure. The findings of 
this study should prompt further research into measuring the impact of diarrhoea on drug 
resistance and treatment failure. 
 
Presence of other medical co-morbidities such as diabetes, hypertension, 
dyslipidemia, ischemic heart disease and renal failure results in patients having to take 
multiple drugs and a high pill burden (also, considered to be a surrogate for treatment 
regimen complexity) has been found to be consistently associated with a higher 
likelihood of discontinuation of antiretroviral therapy[55]. Other co-morbidities such as 
alcoholism may also contribute towards patients being non-adherent to therapy [56]. 
  In a cohort of HIV-infected patients from the USA including 3414 ART-naïve 
patients on HAART with a median follow-up period of 211 days; the main causes for 
discontinuation of therapy were drug toxicity (18.4%), non-compliance(13.4%), and 
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treatment failure(7.5%)[56]. Patients vary in their ability to tolerate side effects. A bad 
physician-patient rapport will lead to reluctance on the part of the patient to report minor 
adverse drug effects and thus contribute to poor adherence and subsequently treatment 
failure.  
 
There is a large inter-individual variability in plasma drug levels achieved in 
patients on antiretroviral therapy. Recent pharmacogenetic studies of antiretroviral drugs 
in humans have reported that several genetic polymorphisms may have a significant 
influence on antiretroviral drug exposure, toxicity and response to treatment[57]. This 
may be another mechanism that could link drug toxicity with treatment failure, other than 
the well known theory of non-adherence/interruption of therapy. 
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CONCLUSIONS 
 
 
 NNRTI resistance with Y181C & K103N mutations and Lamivudine resistance 
with M181V mutation and other TAMs was common (21/21=100%) in this group 
of patients with treatment failure.   
 There is a strong association of treatment failure on anti-retroviral therapy with 
simple clinical parameters – Self reported non-adherence, history of prolonged 
diarrhoea and presence of any adverse drug effect. 
 Adherence >95% is an important determinant for success of antiretroviral 
therapy, Hence stringent adherence counselling is imperative prior to initiation of 
HAART and reinforcement at each subsequent visit is likely to improve treatment 
outcomes.  
 In a patient with history of prolonged diarrhoea, malabsorption should be looked 
for and ruled out, to ensure adequate therapeutic drug levels. Therapeutic drug 
monitoring when available could be used in such situations. 
 Early detection of drug toxicities and prompt management of the same could 
prevent clinically significant interruptions of therapy. 
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LIMITATIONS 
 
 
 
1. Small sample size 
2. Wide confidence intervals may require cautious interpretation of the strength of 
association 
3. A sizeable amount of missing data in the out-patient and in-patient charts of the 
cohort. 
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ANNEXURE: 
 
Proforma 
 
A CASE-CONTROL STUDY ON PREDICTORS OF TREATMENT FAILURE IN PEOPLE LIVING 
WITH HIV/AIDS(PLWHA) ON ART IN A HIV CLINIC FROM SOUTH INDIA 
Proforma No: 
Name:      
Hospital No:    
Sex: Male / Female 
Age in years:               yrs 
Demographics: 
BMI: 
Ht(cm) & Wt.(Kg) 
Kuppuswamy’s Socioeconomic Status Scale 
(A) Education                                                            Score 
1. Profession or Honours                                                   7 
2. Graduate or post graduate                                             6 
3. Intermediate or post high school diploma                     5 
4. High school certificate                                                   4 
5. Middle school certificate                                               3 
6. Primary school certificate                                              2 
7. Illiterate                                                                          1 
(B) Occupation                                                          Score 
1. Profession                                                                     10 
2. Semi-Profession                                                             6 
3. Clerical, Shop-owner, Farmer                                        5 
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4. Skilled worker                                                                4 
5. Semi-skilled worker                                                       3 
6. Unskilled worker                                                            2 
7. Unemployed                                                                   1 
(C) Family income per           Score                              Modified Modified 
month(in Rs)- original                                               for 1998                 for 2007 
1. =2000                                     12                                  =13500               =19575 
2. 1000-1999                              10                                 6750-13499         9788-19574 
3. 750-999                                    6                                 5050-6749           7323- 9787 
4. 500-749                                    4                                 3375-5049           4894- 7322 
5. 300-499                                    3                                 2025-3374           2936-4893 
6. 101-299                                    2                                 676-2024             980-2935 
7. =100                                         1                                  =675                     =979 
Total Score                                                 Socioeconomic class 
26-29                                                                      Upper (I) 
16-25                                                                      Upper Middle (II) 
11-15                                                                      Middle Lower middle (III) 
5-10                                                                        Lower Upper lower (IV) 
<5                                                                           Lower (V) 
 
 
Date of diagnosis of HIV infection:                          (DD/MM/YYYY) 
Risk Factor: Heterosexual / Homosexual / MSM / Blood Transfusion / Needle stick injury /MTCT 
Risk Factor Others: 
Type of test for HIV: ELISA / Western blot / Rapid 
VDRL: Reactive / Non Reactive / Not done 
HBsAg : Reactive / Non Reactive / Not done 
HCV infection: Reactive/ Non-reactive/ Not done 
OI before ART       
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Date OI Proven Presumed 
 TB Pulmonary 
TB Disseminated 
 Bacterial Pneumonia  
  
 TB extrapulmonary             
 Candidiasis  
    1.Oral 
    2. Oesophageal 
  
 Cryptococcosis   
 PCP   
 Cerebral Toxoplasmosis   
 Chronic diarrhea (pathogen) 
     1.  Isospora 
     2.  Cyclospora 
     3.  Microsporidium 
     4.  Cryptosporidium 
     5.  Giardia 
     6.  Others 
  
 Bacterial infections (specify)   
 CMV  
       1.  Eye 
       2.  GI 
       3.  CNS 
       4.  Disseminated 
  
 Neurological Diseases 
        1. Dementia 
        2. Peripheral Neuropathy 
        3. Transverse Myelitis 
        4. GBS 
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        5. CIDP 
        6. Others 
 STI 
1.  Syphilis 
            2.  Herpes Genitalis 
            3.  Herpes Zoster 
            4.  Herpes Symplex 
5.  Gonorrhea 
  
 PMLE   
 Others (specify)   
 
Baseline Investigations (within 30 days before starting ART) 
Hb :                            TC :                                    DC:  
Platelets:    
S. Creatinine 
LFT                               
Lipids 
Chest Xray 
WHO Stage: 1 / 2 / 3 / 4 prior to ART 
Other diseases prior to ART    
                                                                                     Date 
i) Measure of Adherence:  >95% or 80-95% or <80% 
    Self-reported -  
    Pill count/Pill-boxes – 
    Pill Burden -  
ii) Markers for possible malabsorption: 
    Documented gastro-intestinal OI 
    Diarrhea ( Stool frequency ) 
    Albumin (Baseline) 
    Change in Albumin (since HAART) 
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    Weight gain since initiation of ART 
iii) Medical co-morbidities: 
    Diabetes mellitus  
    Hypertension 
    Dyslipidemia 
    Alcoholism 
    Renal failure 
    Others 
iv) Type of treatment failure : 
      Clinical progression/rebound 
      Immunological failure 
      Virological failure 
v) Other drugs with possible interactions: 
        List 
Initial HAART:  WHO – NACO free generic ART/ payment     
  
Regimen:   
Date started:                                                stopped / switched/substituted 
Duration of initial regimen (months):  
If stopped, reason for stopping HAART:  
1. Virologic failure 
2. Immunologic failure 
3. Clinical failure 
4. Drug toxicity 
5. Co-morbidities 
6. IRIS 
7. Drug intolerance 
 
DRUG TOXICITY                                                          Onset of toxicity after HAART (days) 
1. Rash    Date 
2. Lactic acidosis   Date 
3. Hepatitis   Date 
4. Anemia                         Date 
5. Leukopenia   Date 
6. Thrombocytopenia  Date 
7. Peripheral neuropathy   Date 
8. Glucose intolerance/ diabetes  Date 
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9. Dyslipidemia    Date 
10. Lipodystrophy    Date 
11. Pancreatitis    Date 
12.  Renal failure                            Date 
13. Others 
IRIS: Yes /No 
How long after start of HAART 
What IRIS 
Treatment given: Conservative / pathogen specific / steroids/ vitamins 
HAART stopped/ modified 
HAART regimen 2:     Date start:  Date stop: 
Reason ......................................................................................................................... 
HAART regimen 3:     Date start:  Date stop: 
Follow-up 
       Visit Date  
(DD/MM/YYYY) 
Weight   
(Kgs) 
Adherence 
(%) 
Toxicity CD4 Cells 
(/μl) 
Viral load (RNA 
Copies/ml) 
IRIS New 
events 
Baseline        
6 months        
12 months        
18 months        
24 months        
36 months        
48 months        
60 months        
 
Current status :  Alive / Dead 
 
Data sheets: 
 
 
 
